Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Minerva Surgical to $1 from $5 and keeps an Overweight rating on the shares following the Q1 sales beat. With the company having addressed its near-term financing issue, continued sales momentum "should help reinvigorate sentiment on the name," the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on UTRS:
- Minerva Surgical Reports First Quarter 2023 Financial Results
- UTRS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Minerva Surgical to Announce First Quarter 2023 Financial Results
- Minerva Surgical Announces the Appointment of Kaile Zagger as Chief Commercial Officer
- Minerva Surgical Reports Fourth Quarter and Full-Year 2022 Financial Results